Journal article
Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature
Journal of oncology pharmacy practice, Vol.26(1), pp.232-235
01/2020
DOI: 10.1177/1078155219841108
PMID: 30961437
Abstract
Cancer treatment has changed dramatically with the development of oral targeted therapies. Pazopanib, an oral VEGF tyrosine kinase inhibitor, is currently approved for advanced renal cell carcinoma, advanced soft tissue sarcoma, and is being studied for various tumor types. Due to the potential of increased exposure to pazopanib when crushed, pazopanib should be given as an intact whole tablet. Thus, in patients with difficulty swallowing medications or feeding tubes, pazopanib is usually not considered to be an option. Here, we describe two cases which show the administration of crushed pazopanib was feasible and had apparent clinical activity.
Details
- Title: Subtitle
- Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature
- Creators
- Jill Stein - University of Iowa Hospitals and ClinicsMohammed Milhem - University of IowaDaniel Vaena - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Journal of oncology pharmacy practice, Vol.26(1), pp.232-235
- DOI
- 10.1177/1078155219841108
- PMID
- 30961437
- ISSN
- 1078-1552
- eISSN
- 1477-092X
- Language
- English
- Date published
- 01/2020
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359577602771
Metrics
15 Record Views